RANCHO CORDOVA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dalip Sethi, PhD, Senior Director of Product Development and Validation, will be presenting new data on Cesca’s Buoyancy-Activated Cell Sorting (BACS) technology in a poster presentation at the 4th Annual CAR-TCR Summit, which is being held September 4-7, 2018 at the Seaport Hotel & World Trade Center in Boston.
“The development of CAR-T therapies continues to be hindered by manual cell processing techniques used during the manufacturing process,” said Dr. Sethi. “We have developed the X-WASH® device for removing dimethyl sulfoxide (DMSO) from thawed apheresis products that can achieve high cell recovery rates with no significant loss of viability during the wash process. Further, our proprietary BACS technology can efficiently isolate CD3-positive T-cells from these washed fractions with consistently high purity and in less time than traditional manual processing methods. We are pleased to present this data at the upcoming Summit.”
Details of the poster presentation are as follows:
|Title:||DMSO Removal & CD3+ Cell Selection from Cryopreserved Apheresis Products Using Novel BACS Technology|
|Date:||September 6, 2018|
|Time:||8:00 a.m. ET|
|Location:||Commonwealth Hall Salon C, Harbor Level|
Dr. Sethi will also deliver a spotlight presentation on the Company’s automated, CAR-T cell manufacturing capabilities on Wednesday, September 5, 2018 at 4:10 p.m. ET during the “Tech Slam at the Innovation Hub.”
The CAR-TCR Summit brings together over 90 world-class speakers and more than 700 attendees in the only end-to-end conference dedicated to successfully bringing the next generation CAR-T and TCR cell immunotherapies to market. For more information about the CAR-TCR Summit, go to: http://car-tcr-summit.com/.
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics’ forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics’ annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
Cesca Therapeutics Inc.